BioCentury
ARTICLE | Clinical News

GSK3359609: Phase I started

July 18, 2016 7:00 AM UTC

GlaxoSmithKline began the open-label, dose-escalation, dose-expansion, international Phase I INDUCE-1 trial to evaluate IV GSK3359609 every 3 weeks alone and in combination with IV Keytruda pembroliz...